Kopran Ltd

Kopran Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kopran Ltd

₹ 259 1.61%
25 Jul - close price
kopran.com BSE: 524280 NSE: KOPRAN
About

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Key Points

Business Verticals FY24
1. API Vertical (~54%): WOS Kopran Research Laboratories operates the API vertical. [1] The co. undertakes development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients and Advanced Intermediates. It is one of the leaders in Atenolol. [2]

Website BSE NSE
  • Market Cap ₹ 1,249 Cr.
  • Current Price ₹ 259
  • High / Low ₹ 292 / 160
  • Stock P/E 36.0
  • Book Value ₹ 86.5
  • Dividend Yield 1.16 %
  • ROCE 11.4 %
  • ROE 8.53 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 70.4%

Cons

  • Stock is trading at 2.99 times its book value
  • The company has delivered a poor sales growth of 11.4% over past five years.
  • Company has a low return on equity of 7.02% over last 3 years.
  • Earnings include an other income of Rs.16.7 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
62 29 56 55 64 71 54 68 80 66 99 82 91
55 29 52 51 58 65 48 62 73 65 90 70 75
Operating Profit 7 1 5 3 7 6 6 6 7 1 9 12 15
OPM % 11% 2% 8% 6% 10% 9% 11% 9% 9% 1% 9% 15% 17%
2 2 2 2 2 0 15 1 2 1 6 1 8
Interest 1 1 1 1 1 0 1 1 1 1 1 1 2
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 8 1 5 3 7 5 19 5 8 0 13 11 21
Tax % 27% 24% 24% 22% 33% 25% 5% 25% 26% 30% 15% 24% 26%
6 1 4 2 5 4 18 4 6 0 11 9 15
EPS in Rs 1.30 0.20 0.87 0.54 0.99 0.79 3.71 0.84 1.14 0.03 2.21 1.77 3.18
Raw PDF
Upcoming result date: 8 August 2024

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
250 302 326 187 182 154 197 179 223 205 273 337
216 264 294 162 164 145 174 156 193 189 245 301
Operating Profit 34 38 32 25 17 9 23 23 30 15 28 37
OPM % 14% 13% 10% 13% 10% 6% 12% 13% 14% 8% 10% 11%
2 6 6 -0 9 8 3 2 10 8 16 17
Interest 12 14 13 10 10 7 5 6 4 3 3 4
Depreciation 12 12 10 3 3 3 3 3 4 4 4 5
Profit before tax 12 17 15 11 13 7 17 16 33 16 37 45
Tax % 0% 0% 0% 0% 36% 32% 25% 29% 28% 27% 15% 22%
12 17 15 11 8 5 13 11 23 12 31 35
EPS in Rs 3.09 4.36 3.77 2.64 1.97 1.09 3.00 2.59 5.43 2.44 6.48 7.19
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 55% 123% 46% 42%
Compounded Sales Growth
10 Years: 1%
5 Years: 11%
3 Years: 15%
TTM: 24%
Compounded Profit Growth
10 Years: 11%
5 Years: 22%
3 Years: 14%
TTM: 11%
Stock Price CAGR
10 Years: 17%
5 Years: 50%
3 Years: 2%
1 Year: 40%
Return on Equity
10 Years: 7%
5 Years: 7%
3 Years: 7%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 39 39 41 43 43 43 43 43 43 48 48 48
Reserves 80 98 122 145 158 162 175 186 204 331 347 369
111 137 46 42 56 52 50 46 16 37 28 23
63 55 65 49 54 42 50 52 61 48 82 71
Total Liabilities 293 329 275 279 311 300 319 327 324 464 506 511
106 103 33 35 39 38 42 43 47 46 47 57
CWIP 1 1 0 0 4 8 7 7 3 3 4 0
Investments 7 7 46 156 157 157 158 158 159 259 260 261
179 219 195 88 110 97 112 119 115 155 195 193
Total Assets 293 329 275 279 311 300 319 327 324 464 506 511

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
14 2 53 19 4 12 12 10 49 -38 17 35
-8 -9 -10 -4 -9 -2 -4 1 -9 -100 10 -6
-12 7 -43 -15 5 -11 -7 -11 -40 138 -26 -24
Net Cash Flow -7 0 -0 0 -0 -0 -0 0 0 -0 1 5

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 72 66 33 38 77 48 83 86 81 106 112 95
Inventory Days 87 104 24 90 84 119 78 149 73 119 98 78
Days Payable 111 69 63 114 120 115 101 114 106 85 128 82
Cash Conversion Cycle 48 100 -6 14 41 52 60 121 48 139 82 91
Working Capital Days 76 110 145 54 89 105 94 114 86 192 150 126
ROCE % 11% 11% 12% 10% 10% 5% 9% 8% 14% 6% 9% 11%

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
43.78% 43.78% 44.25% 44.25% 44.25% 44.29% 44.29% 44.49% 44.49% 44.49% 44.49% 44.49%
0.27% 0.75% 0.53% 0.50% 0.51% 0.34% 0.41% 0.34% 0.39% 0.48% 0.84% 0.68%
0.46% 0.16% 0.14% 0.13% 0.14% 0.14% 0.14% 0.14% 0.35% 0.14% 1.20% 0.14%
55.50% 55.31% 55.07% 55.11% 55.09% 55.22% 55.15% 55.03% 54.78% 54.88% 53.47% 54.68%
No. of Shareholders 38,19537,82239,90640,88341,76842,03441,56744,03853,79151,63650,85051,492

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls